Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nimotuzumab, Toripalimab, and Chemotherapy in Locally Advanced Tonsillar Cancer
NCT07353723Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab, toripalimab in Tonsillar squamous cell carcinoma (TSCC), sponsored by Tangdu Hospital. Started Nov 2025; status: recruiting.
02
Drugs
nimotuzumabtoripalimab
03
Conditions
Tonsillar squamous cell carcinoma (TSCC)
Beyond the preview
Go deeper on NCT07353723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353723.